



February 9, 2016

To whom it may concern:

VITAL KSK HOLDINGS, INC.

Representative: Mr. Taisuke Murai, President & CEO
(Code number: 3151, Tokyo Stock Exchange, First Section)

Contact: Mr. Kiharu Takahashi, General Manager of
Accounting and Finance
(Tel. +81-3-3275-3303)

Notice of Revision of Earnings Forecast

In light of recent earnings trends and other factors, VITAL KSK HOLDINGS, INC. (hereinafter the “Company”) hereby announces a revision of its earnings forecast released on October 30, 2015, as follows.

1. Revision of consolidated earnings forecast for the fiscal year ending March 31, 2016

(April 1, 2015 to March 31, 2016)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of parent	Net income per share
Previously announced forecast (A)	Million yen 600,000	Million yen 3,000	Million yen 6,500	Million yen 4,200	Yen 75.11
Revised forecast (B)	613,500	5,000	8,700	5,700	101.94
Difference (B-A)	13,500	2,000	2,200	1,500	
Increase/decrease (%)	2.3	66.7	33.8	35.7	
(Reference) Results for the previous fiscal year (ended March 31, 2015)	548,012	1,812	6,125	4,527	79.51

2. Reasons for the revision

As sales of new drugs including hepatitis C medications were significantly higher than forecast, net sales, operating income, ordinary income and net income attributable to owners of parent are expected to surpass earlier forecasts. Therefore, the consolidated earnings forecast has been revised as shown above.

Note: The above earnings forecasts are compiled based on materials available at the time of announcement. Actual results may differ from forecasts due to various factors.